A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

Recruiting now

Conditions studied: Non-Small-Cell Lung

In brief

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Key facts

Study ID

NCT07316062

Run by

AstraZeneca

People needed

3000

Starts

2026-04-29

Expected to finish

2029-04-30

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage I-III at initial NSCLC diagnosis
• Aged ≥18 years at first diagnosis of NSCLC
• Timeframe of NSCLC diagnosis:
• For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

You may not qualify if…

• NSCLC is not the primary cancer diagnosis
• Patients with a recent history of other tumor or concurrent other tumor
• Patients participating in interventional clinical trials at time of initial diagnosis
• Patients with positive pregnancy status at the time of diagnosis

Where it is running

• Research Site — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.